AU7779200A

AU7779200A - Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction

Info

Publication number: AU7779200A
Application number: AU77792/00A
Authority: AU
Inventors: Klaus Diedrich; Jurgen Engel; Ricardo Felberbaum; Wolfgang Kupker; Hilde Riethmuller-Winzen
Original assignee: Zentaris AG
Current assignee: Aeterna Zentaris GmbH
Priority date: 1999-09-23
Filing date: 2000-09-20
Publication date: 2001-04-24
Anticipated expiration: 2020-09-20
Also published as: KR20020035879A; PL353244A1; TWI267373B; KR100772852B1; SK3752002A3; IL148185A0; JP2012051920A; NO20021430D0; HUP0202741A3; BR0014198A; UA73956C2; JP2003509467A; CN1376070A; NO331198B1; RU2255759C2; NZ534836A; AU769482B2; BG66128B1; TR200200738T2; BG106584A

Description

WO 01/21194 PCT/EPOO/09212 -1 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction 5 Field of Invention Endometriosis is one of the most frequently encountered pathologies diagnosed amongst gynecological patients. For example, between 10% and 25% of women o presenting with gynecological symptoms in UK and in the USA are affected. Clinical diagnosis is made usually by laparoscopic observation of hemorrhagic or fibrotic foci on the pelvic organs. The ectopic endometrial tissue responds to ovarian hormones undergoing cyclic changes. The cyclical bleeding from the endometric deposit contributes to a local inflammatory reaction. Endometriosis commonly affects women 15 during their childbearing years with an incidence of at least 1% (see Shaw, R.W. (1993), An Atlas of Endometriosis. The Parthenon Publishing Group). Endometriosis is usually classified into endometriosis (genitalis) interna (adenomyosis), endometriosis genitalis externa and endometriosis extragenitalis. 20 Chronic pelvic pain may occur either in relation to endometriosis or as an independent disease. Fallopian tube obstruction (FTO) is a relatively common disease and may account to 25 for up to 20 % of cases of tubal infertility (see Winfield, A.C. et al., Apparent cornual occlusion in hysterosalpingography: Reversal by glucagon. AJR Am J Roentgenol 1982; 139: 525 - 527). Background information and Prior Art 30 Sampson suggested that menstrual regurgitation and subsequent implantation of endometrial tissue on the peritoneal face results in endometriosis [Sampson, J.A.

WO 01/21194 PCT/EPOO/09212 -2 (1927), Peritoneal endometriosis due to menstrual dissemination of the endometrial tissue into the peritoneal cavitiy. Am. J. Obstet. Gynecol., 14, 422.] Several aetiologic factors may be involved in the pathogenesis of endometriosis: 5 Dmowski et. al. suggested that genetic and immunological factors lead to endometriosis [Dmowski, W.P., Steele, R.W. and Baker, G.F. (1981). Deficient cellular immunity in endometriosis. Am. J. Obstet. Gynecol., 141, 377] Vascular and lymphatic embolization to distant sites has been demonstrated and explains the (rare) finding of endometriosis outside the peritoneal cavity, e.g. skin, 10 lung, kidney. Cells lining the Mullerian duct arise from primitive cells which differentiate into peritoneal cells and the cells on the surface of the ovaries. It is proposed that these adult cells undergo de-differentiation back to their primitive origin and then transform into endometrial cells [ Levander, G. (1941), Bone formation by induction. An 15 experimental study. Arch. Klin. Chir., 202, 497] Dysmenorrhea, acute or chronic pelvic pain, dyspareunia, and infertility perform the most frequent clinical symptoms reported. FTO represents a heterogenous group of underlying pathology, preliminary intrinsic 20 occlusion or extrinsic compression from estrogen-sensitive disorders, such as endometriosis, adenomyosis, endosalpingiosis, and myomata. FTO is frequently diagnosed by hysterosalpingography, besides laparascopy. First choice of treatment comprises laparoscopic removal of endometric lesions. 25 This procedure may be followed by the treatment with Danazol or LHRH agonist (for a period of six months). Women being treated with Danazol might experience gastrointestinal and hepatic disorders as well as severe androgenic side effects. It was also proposed from a theoretical viewpoint for treatment of endometriosis and uterine myoma to use the immediate suppression by administration of a LHRH 30 antagonist to reducing the duration of treatment and faster improvement of subjective symtoms [Th. Reissmann et al. Human Reproduction vol. 10 No. 8 pp.1974-1981,(1995)] WO 01/21194 PCT/IEPOO/09212 -3 Further Hodgen teaches in the US Patent 5,658,884 a regime for therapeutic management of a gonadal dependent condition by reducing the estrogen supply by means of long-term administration of an GnRH antagonist for 6 months or longer in an amount effective to inhibit proliferation of endometrial tissue without substantially 5 stopping the production of endogenous estrogen. For this purpose, Hodgen teaches such a regimen or dose of GnRH antagonist to achieve a 24 hour serum estradiol level in the range of about 25 to 50 and preferably about 35 to 45 pg/ml. However, Hodgen does not describe estradiol serum levels oscillating between 50 pg/ml and 75 pg/ml. Moreover, Hodgen only teaches in the US Patent 5,658,884 a continuous 10 long-term treatment (on a daily or periodic basis, the latter meaning a weekly or monthly administration) but not a short-term induction treatment for only 4 to 12 weeks. Hodgen also does not describe any combination therapy comprising the GnRH antagonist in the treatment of endometrosis. The treatment is only described on monkeys and also includes the performance of a costly and repeated 15 progesterone challenge test to provide an 24 hour average serum estradiol level of 30 to 50 pg/mI. As a consequence of the flare-up effect of LHRH-agonistic therapy an exacerbation of symptoms might occur during some days. Following prolonged 20 treatment which is required to avoid the re-proliferation of endometric tissue hormonal withdrawal symptoms as well as demineralization of bones occur. Therefore, effective drug therapy should immediately reduce the residual extrauterine endometrial tissue present after laparoscopic surgery. Duration of 25 therapy should be only 4 to 12 weeks without the occurrence of any major hormonal withdrawal symptoms or ovarian cyst formation. LHRH antagonists exert an immediate onset of hormonal suppression, and therefore benign gynecological tumors, such as uterine fibroids decrease within short time 30 [Human Reproduction 1998, 13] Object of the Invention WO 01/21194 PCT/EPOO/09212 -4 The present invention relates to the improvement of the medical treatment of extrauterine proliferation of endometrial tissue, i. e. the administration of LHRH antagonists in patients with clinical symptoms of endometriosis, the improvement consisting of : 5 immediate reduction of ectopic endometrial tissue immediate cessation of symptoms, e.g. severe pain, chronic pelvic pain and dysmenorrhea prevention of any progress of the disease avoidance of hormonal withdrawal symptoms 10 prevention of ovarian cyst formation, demineralization of bones as well as of gastrointestinal or hepatic disorders. The inventive medical therapy can start in the early to mid follicular phase, preferably on cycle day one to three. During the treatment the estradiol serum concentration levels are kept between 35 pg/ml and 80 pg/ml, preferably between 15 about 45-75 pg/ml, more preferably between about 50-75 pg/ml. The LHRH antagonist is administered only for 4 to 12 weeks (short-term induction treatment), either by daily, weekly or monthly administration. Following the short-term induction treatment, the administration of a contraceptive, a non-steroidal anti-rheumatic, an analgetic, an androgen other than 17-alpha-alkyl substituted testosterone or any 20 combinations thereof is provided according to the present invention. Summary of the Invention 25 In the treatment of extrauterine endometrial tissue with an LHRH antagonist, therapy is started on menstrual cycle day one to three. Before starting LHRH antagonist therapy the diagnosis is performed by laparoscopy. In cases of severe pain, LHRH antagonist therapy might be initiated without prior laparascopy. 30 Therapy will continue until clinical symptomatology has resolved and no proliferation of the endometrium is seen. Due to the immediate onset of suppression of the gonadotropins LH and FSH as well of sex steroids estradiol and progesterone no WO 01/21194 PCT/EPOO/09212 -5 further proliferation of the endometrium occurs. Benign tumors or other sex steroid dependent lesions, like endometriosis decrease within four to twelve weeks of therapy. Due to the lack of flare-up no ovarian cysts develop. 5 Furthermore, no hormonal withdrawal symptoms are seen as the estradiol values are kept in the range of the early follicular phase of 35 to 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml without further increase or decrease. No titering of the dosage of the LHRH antagonist , e.g. by conducting a costly progesterone challenge test, is necessary. 10 The method of therapeutic management of extrauterine proliferation of endometrial tissue the improvement according to the invention therefore embraces: immediate reduction of ectopic endometrial tissue prevention of any progress of the disease 15 avoidance of hormonal withdrawal symptoms prevention of ovarian cyst formation, demineralization of bones as well as of gastrointestinal or hepatic disorders start of medical therapy on cycle day one to three and maintenance of estradiol levels at values of the early follicular phase throughout the entire duration of 20 treatment by means of administration of a LHRH antagonist wherein the antagonist is preferabely cetrorelix, teverelix, ganirelix, antide or abarelix. The antagonist can also be the LHRH antagonist D-63153 (Ac-D-Nal-D-pCI-Phe-D-Pal-Ser-N-Me-Tyr-D Hci-Nle-Arg-Pro-D-Ala-NH2) as described in the German Patent Application No. 199 11 771.3 filed on March 11, 1999. 25 The LHRH antagonist may be given for 4 to 12 weeks in a weekly dose of 3 to 10 mg per week or for 4 to 12 weeks in a daily dose of 0.25 mg to 0.5 mg/day. It is also possible to give the LHRH antagonist 4 to 12 weeks in a monthly dose of 30 12 to 40 mg per month. In a repeat therapeutic treatment the LHRH antagonist is given for 4 to 12 weeks and the treatment is repeated two or three times a year, whereby a repeated WO 01/21194 PCT/EPOO/09212 -6 treatment does not following directly after a short-term induction treatment. Usually a period of time of weeks or months, where no LHRH antagonist is administered, is between the end of the short-term induction treatment and the start of the repeat treatment. 5 To demonstrate the feasibility to maintain a low estradiol secretion under adjusted LHRH- antagonist treatment so that a therapeutic suppression occurs without withdrawal symtoms nine patients with confirmed endometriosis were treated with 3 mg of Cetrorelix acetate s.c. by weekly administration for 8 weeks. While patients io compliance was excellent avoiding any hot flushes or other withdrawal symptoms and without any progress of the disease confimed by 2 nd look laparascopy the mean estradiol serum concentrations oscillated between 37 pg/ml and 64 pg/ml, preferably between 45-75 pg/ml, more preferably between about 50-75 pg/ml. Histological biopsies showed no proliferation of the endometrium at the end of treatment. No 15 ovarian cyst formation occurred. The figure 1 shows the continuous estradiol suppression to values of the early follicular phase (range of 35 pg/mI to 80 pg/mI, preferably between 45-75 pg/ml, more preferably between about 50-75 pg/ml) obtained in patients with endometriosis 20 by a weekly dose of 3 mg of Cetrorelix (LHRH antagonist) for 8 weeks. Immediate and continuous suppression of estradiol levels is obtained without any signs of estradiol withdrawal symptoms and without proliferation of the endometrium at the end of treatment. 25 Fig. 2 shows estradiol serum levels after administration of cetrorelix at a weekly dose of I mg resp. 3 mg once per week. The estradiol serum levels are between about 35 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50 75 pg/ml. 30 The endometriosis patient with distinctive symptomatic pain is suffering from a chronic disease. Surgical methods in sense of curative therapy as well as medicinal treatment to suppress the sexual steroid secretion of the patient often result only in a WO 01/21194 PCT/EPO/09212 temporary improvement. The relapse rate of the discomforts is very high and about 70% within 5 years after finishing therapy (Schweppe, 1999). At the same time the radical surgical therapy and the suppression of the estrogen 5 secretion leads to considerable side effects. The radical surgical therapy in sense of hysterectomy with bilateral adnexectomy is no adequate therapy for the younger, premenopausal woman. The chronical lack of estrogen leads to the following vegetative symptoms: hot flashes, sweating, dryness of the vagina, depressive feelings and also holds the risk of osteoporosis. The alternative therapy with the io synthetic steroidal compound Danazol may cause virilizing symptoms because of the androgenic effect. Aim of the medicinal therapy of patients with endometriosis with symptomatic pain is to obtain a treatment without side effects, especially avoiding the negative effects of 15 estrogen suppression and which is long-lasting after finishing therapy. The specific pharmacological mode of action of LHRH antagonists allows new possibilities for treatment of endometriosis. The weekly administration of an adequate dose of an LHRH antagonist, e.g. 3 mg 20 Cetrotide* s.c./ per week over a period of eight weeks leads to a controlled suppression of estrogen secretion so that serum concentrations between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably between about 50-75 pg/ml are obtained. In this serum concentration range no vegetative symptoms arise. Also the development of osteoporosis can be avoided. 25 The symptomatic pain will be effectively suppressed in all stages of the disease (rAFS I - IV). In the stages rAFS I - I a clinical regression of the disease in sense of decrease of the implantation area is noticed (Felberbaum et. al., 2000). In a preferred embodiment of this invention, after this treatment period of eight to 30 twelve weeks the patient could take a contraceptive, preferably an oral contraceptive, preferably with gestagen components, unless there is a wish for pregnancy. In this connection combinations with Lynestronol 2 mg with 0,04 mg WO 01/21194 PCT/EP00/09212 -8 Ethinylestradiol or 2,5 mg Lynestrenol with 0,05 mg of Ethinylestradiol (e.g. Yermonil*, Lyn-ratiopharm-Sequenz*) have to be mentioned. A combination therapy with androgens other than 17-alpha-alkyl substituted 5 testosterones such as danazol may also be applied subsequently to the short-term induction regimen with the LHRH antagonist either alone or in combination with non steroidal anti-rheumatics and/or analgetics. An example for a suitable androgene is halotestinTM (fluoximesterone). 10 The treatment with a contraceptive, preferably an oral contraceptive, preferably containing gestagens, should be individually continued until typical pain sensation occurs. In this stage the patient will have relatively small menstrual bleeding as an effect of the gestagen component of this contraceptive, preferably oral contraceptive. For covering also the especially critical pre-menstrual and menstrual days with 15 regard to pain sensation in this phase a concomitant medication with appropriate non-steroidal anti-rheumatic drugs, e.g. diclophenac, ibuprofen, indometeacin, oxicam derivates or acetylsalicylic acid may be given. Also an analgetic such as flupirtinmaleat (Katadolon*) can be administered. 20 If further pain symptoms occur during this combination therapy with gestagenic contraceptives, preferably oral contraceptives, a daily, weekly or monthly therapy with the adequate dose of an LHRH antagonist as described above may be repeated. Detailed information on the respective treatment options are given below. If the patient is absolutely free of pain treatment can be changed to gestagenic 25 contraceptive, preferably oral contraceptive,s in combination with concomitant medication of appropriate non-steroid anti-rheumatic drugs or analgetics. This therapy using the intermittent administration of an LHRH antagonist leads to a new and innovative unlimited treatment without side effects and lowers treatment 30 burden for the patient significantly.

WO 01/21194 PCT/IEPOO/09212 Pharmaceutical Formulations Suitable for Treatment Pharmaceutical formulations of the LHRH antagonist suitable for the therapeutic 5 management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction may be for example a) acetate salt formulations in the concentration of 1 mg/1 ml or lower where the powder may be dissolved in Water for Injection (Wfl) or in Gluconic Acid (GA); 10 b) acetate salt formulations in the concentration of 1.5 mg/1 ml to 5.0 mg /1 ml, preferably 2.5 mg/1 ml where the powder may be dissolved in Water for Injection (Wfl) or in Gluconic Acid (GA); 15 c) pamoate salt formulations in the concentration of 10 mg/1 ml to 30 mg/1 ml, preferably 15 mg/1 ml where the lyophylisate powder may be dissolved in Gluconic Acid (GA) or in Water for Injection (Wfl. According to one aspect of the present invention in the method of therapeutic 20 management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), the improvement consisting of administration of an LHRH antagonist in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, whereby subsequently the administration of the LHRH antagonist is ceased, is provided. 25 The duration of the short term induction treatment is about 4 to about 12 weeks, that means that the treatment can be between about 28 to about 84 days or from about one to about three months. 30 According to another aspect of the present invention in a method as mentioned above the improvement is provided, wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and WO 01/21194 PCT/EPOO/09212 -10 about 80 pg/mI, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml. According to another aspect of the present invention in a method as mentioned 5 above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive. According to another aspect of the present invention in a method as mentioned 10 above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent. According to another aspect of the present invention in a method as mentioned 15 above the improvement is provided, characterized in that the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic. According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction 20 treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone. According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the short-term induction 25 treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. 30 According to another aspect of the present invention in a method as mentioned above the improvement is provided, characterized in that the LHRH antagonist is WO 01/21194 PCT/EPOO/09212 -11 administered starting in the early to mid follicular phase, preferably on cycle day one to three. According to another aspect of the present invention in a method as mentioned 5 above the improvement is provided, characterized in that the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153. According to another aspect of the present invention in a method as mentioned io above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week. According to another aspect of the present invention in a method as mentioned 15 above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day. According to another aspect of the present invention in a method as mentioned 20 above the improvement is provided, characterized in that the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month. According to another aspect of the present invention in a method as mentioned 25 above the improvement is provided, characterized in that the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year. According to a further aspect of the present invention a pharmaceutical composition 30 for treating extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO) comprising an LHRH antagonist and optionally one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic agent, an WO 01/21194 PCT/IEPOO/09212 androgen agent other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, optionally together with pharmaceutically acceptable excipients, whereby the LH-RH antagonist is administered to a patient in need thereof in a short term induction treatment for a period of about 4 to 12 weeks, then 5 the administration of the LH-RH antagonist is ceased and optionally the one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are administered together or separately to the patient is provided. 10 Suitable excipients and dosage forms are for example described by K.H. Bauer, K.

H. Fromming and C. FOhrer, Lehrbuch der Pharmazeutischen Technologie, 6 t' edition, Stuttgart 1999, pages 163-186 (excipients) and pages 227-386 (dosage forms), including the references as cited therein. 15 The LH-RH antagonist can be administered for example sucutaneous (s.c.), intramuscular (i.m.) or inhalative. The agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or 20 any combinations thereof can be administered as known in the art (see for example the German, European or U.S. pharmacopoeia), preferably oral or inhalative. According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered such 25 that the estrogen serum concentration level is between about 35 pg/mI and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml. According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the 30 LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.

WO 01/21194 PCT/EPOO/09212 -13 According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent. 5 According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic. 10 According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17 alpha-alkyl substituted testosterone. 15 According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an 20 androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered 25 starting in the early to mid follicular phase, preferably on cycle day one to three. According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153. 30 According to another aspect of the present invention, a pharmaceutical composition as mentioned above is provided wherein the LHRH antagonist is administered during WO 01/21194 PCT/EPOO/09212 -14 the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week. According to another aspect of the present invention, a pharmaceutical composition 5 as mentioned above is provided wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day. According to another aspect of the present invention, a pharmaceutical composition io as mentioned above is provided wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month. According to another aspect of the present invention, a pharmaceutical composition 15 as mentioned above is provided wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year. According to another aspect of the present invention, a pharmaceutical composition 20 as mentioned above is provided, wherein the the one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are in the same or separate dosage forms. 25 According to another aspect of the present invention, a use of an LH-RH antagonist for the preparation of a medicament for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a 30 short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment and then the administration of the LHRH antagonist is ceased, is provided.

WO 01/21194 PCT/IEPOO/09212 -15 According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml. 5 According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive. 10 According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent. 15 According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic. 20 According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17 alpha-alkyl substituted testosterone. 25 According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive,, a non-steroidal anti-rheumatic agent, an analgetic, an 30 androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.

WO 01/21194 PCT/EPOO/09212 -16 According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three. 5 According to another aspect of the present invention, a use of an LH-RH antagonist as mentioned above is provided, wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153. According to another aspect of the present invention, a use of an LH-RH antagonist 10 as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a weekly dose of 3 to 10 mg per week. According to another aspect of the present invention, a use of an LH-RH antagonist 15 as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a daily dose of 0.25 mg to 0.5 mg/day. According to another aspect of the present invention, a use of an LH-RH antagonist 20 as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month. According to another aspect of the present invention, a use of an LH-RH antagonist 25 as mentioned above is provided, wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year. According to another aspect of the present invention, a use of an LH-RH antagonist 30 and one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone, or any combinations thereof, for the preparation of a medicament for the therapeutic WO 01/21194 PCT/IEPOO/09212 -17 management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, then the administration of the LHRH 5 antagonist is ceased and the one or more active agent selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone, or any combinations thereof, are administered together or separately to the patient, is provided. 10 According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/mI, 15 more preferably about 50-75 pg/ml. According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short term induction treatment with the LHRH antagonist is followed by administration of a 20 contraceptive, preferably an oral contraceptive. According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short term induction treatment with the LHRH antagonist is followed by administration of a 25 non-steroidal anti-rheumatic agent. According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short term induction treatment with the LHRH antagonist is followed by administration of 30 an analgetic. According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the short- WO 01/21194 PCT/EPOO/09212 -18 term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone. According to another aspect of the present invention the use of an LH-RH antagonist 5 and one or more active agents as mentioned above is provided, wherein the short term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted io testosterone or any combinations thereof. According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on 15 cycle day one to three. According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, 20 antide, abarelix and D-63153. According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 25 weeks at a weekly dose of 3 to 10 mg per week. According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is administered during the short-term induction treatment for 4 to 12 30 weeks at a daily dose of 0.25 mg to 0.5 mg/day. According to another aspect of the present invention the use of an LH-RH antagonist and one or more active agents as mentioned above is provided, wherein the LHRH WO 01/21194 PCT/EPOO/09212 -19 antagonist is administered during the short-term induction treatment for 4 to 12 weeks at a monthly dose of 12 to 40 mg per month. According to another aspect of the present invention the use of an LH-RH antagonist 5 and one or more active agents as mentioned above is provided, wherein the LHRH antagonist is given for the induction treatment during 4 to 12 weeks and the treatment is repeated two or three times a year.

Claims

1. In the method of therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), 5 the improvement consisting of administration of an LHRH antagonist in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, whereby subsequently the administration of the LHRH antagonist is ceased. 10 2. A method according to claim 1 wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about

50-75 pg/ml. 15 3. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive. 4. A method according to claim 1 wherein the short-term induction treatment with 20 the LHRH antagonist is followed by administration of a non-steroidal anti rheumatic agent. 5. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic. 25 6. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone. 30 7. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an WO 01/21194 PCT/EPOO/09212 analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. 8. A method according to claim 1 wherein the LHRH antagonist is administered 5 starting in the early to mid follicular phase, preferably on cycle day one to three. 9. A method according to claim 1 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153. 10 10.A method according to claim 1 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to 10 mg per week. 11. A method according to claim 1 wherein the LHRH antagonist is administered 15 during the short-term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to 0.5 mg/day. 12. A method according to claim I wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly 20 dose of about 12 to 40 mg per month. 13. A method according to claim 1 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year. 25 14. A pharmaceutical composition for treating extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO) comprising an LHRH antagonist and optionally one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non 30 steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha alkyl substituted testosterone or any combinations thereof, optionally together with pharmaceutically acceptable excipients, whereby the LH-RH antagonist is administered to a patient in need thereof in a short term induction treatment for a WO 01/21194 PCT/EPOO/09212 period of about 4 to 12 weeks, then the administration of the LH-RH antagonist is ceased and optionally the one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl 5 substituted testosterone or any combinations thereof, are administered together or separately to the patient. 15. Pharmaceutical composition according to claim 14 wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between 10 about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/mi, more preferably about 50-75 pg/ml. 16. Pharmaceutical composition according to claims 14 or 15 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a 15 contraceptive, preferably an oral contraceptive. 17. Pharmaceutical composition according to any one of the claims 14 to 16 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent. 20 18. Pharmaceutical composition according to any one of the claims 14 to 17 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic. 25 19. Pharmaceutical composition according to any one of the claims 14 to 18 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone. 30 20. Pharmaceutical composition according to any one of the claims 14 to 19 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non- WO 01/21194 PCT/EPOO/09212 -23 steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha alkyl substituted testosterone or any combinations thereof. 21. Pharmaceutical composition according to any one of the claims 14 to 20 wherein 5 the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three. 22. A pharmaceutical composition according to any one of claims 14 to 21 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, 10 ganirelix, antide, abarelix and D-63153. 23. Pharmaceutical composition according to any one of claims 14 to 22 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to about 10 mg per week. 15 24. A pharmaceutical composition according to any one of claims 14 to 23 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to about 0.5 mg/day. 20 25. Pharmaceutical composition according to any one of claims 14 to 24 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to 40 mg per month. 26. Pharmaceutical composition according to any one of claims 14 to 25 wherein the 25 LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year. 27. Pharmaceutical composition according to any one of claims 14 to 26, wherein the the one or more active agents selected from the group consisting of a 30 contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are in the same or separate dosage forms. WO 01/21194 PCT/IEPOO/09212 28. Use of an LH-RH antagonist for the preparation of a medicament for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH 5 antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment and then the administration of the LHRH antagonist is ceased. 29. Use of an LH-RH antagonist according to claim 28 wherein the LHRH antagonist 10 is administered such that the estrogen serum concentration level is between about 35 pg/mI and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml. 30. Use of an LH-RH antagonist according to claim 28 or 29 wherein the short-term 15 induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive. 31. Use of an LH-RH antagonist according to any one of claims 28 to 30 wherein the short-term induction treatment with the LHRH antagonist is followed by 20 administration of a non-steroidal anti-rheumatic agent. 32. Use of an LH-RH antagonist according to any one of claims 28 to 31 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic. 25 33. Use of an LH-RH antagonist according to any one of claims 28 to 32 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone. 30 34. Use of an LH-RH antagonist according to any one of claims 28 to 33 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from WO 01/21194 -25- PCT/EPOO/09212 the group consisting of a contraceptive, preferably an oral contraceptive, a non steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha alkyl substituted testosterone or any combinations thereof. 5 35. Use of an LH-RH antagonist according to any one of claims 28 to 34 wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three. 36. Use of an LH-RH antagonist according to any one of claims 28 to 35 wherein the 10 LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153. 37. Use of an LH-RH antagonist according to any one of claims 28 to 36 wherein the LHRH antagonist is administered during the short-term induction treatment for 15 about 4 to 12 weeks at a weekly dose of about 3 to about 10 mg per week. 38. Use of an LH-RH antagonist according to any one of claims 28 to 37 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to about 0.5 mg/day. 20 39. Use of an LH-RH antagonist according to any one of claims 28 to 38 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to about 40 mg per month. 25 40. Use of an LH-RH antagonist according to any one of claims 28 to 39 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year. 41. Use of an LH-RH antagonist and one or more active agents selected from the 30 group consisting of a contraceptive, preferably an oral contraceptive, a non steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha alkyl substituted testosterone, or any combinations thereof, for the preparation of a medicament for the therapeutic management of extrauterine proliferation of WO 01/21194 PCT/EPOO/09212 endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), whereby the LHRH antagonist is administered in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, then the administration of the LHRH antagonist is ceased and 5 the one or more active agent selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone, or any combinations thereof, are administered together or separately to the patient. 10 42. Use of an LH-RH antagonist and one or more active agents according to claim 41, wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/mI, more preferably about 50-75 pg/ml. 15 43. Use of an LH-RH antagonist and one or more active agents according according to claims 41 or 42 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive. 20 44. Use of an LH-RH antagonist and one or more active agents according according according to any one of claims 41 to 43 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non steroidal anti-rheumatic agent. 25 45. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 44 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic. 30 46. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 45 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha alkyl substituted testosterone. WO 01/21194 PCT/IEPOO/09212 -27 47. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 46 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more 5 active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. 10 48. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 47 wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three. 49. Use of an LH-RH antagonist and one or more active agents according to any one 15 of claims 41 to 48 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153. 50. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 49 wherein the LHRH antagonist is administered during the short 20 term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to 10 mg per week.

51. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 50 wherein the LHRH antagonist is administered during the short 25 term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to 0.5 mg/day.

52. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 51 wherein the LHRH antagonist is administered during the short 30 term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to 40 mg per month. WO 01/21194 PCT/EPOO/09212

53. Use of an LH-RH antagonist and one or more active agents according to any one of claims 41 to 52 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year. 5